GLP-1s, Eating Disorders, and Disordered Eating: The Research and the Risks

Wilfong Nutrition LLC | Austin, Texas

Nearly a third of people with eating disorders reported using a GLP-1 medication, according to a 2026 survey. These medications, sold as Ozempic, Wegovy, Mounjaro, and Zepbound, are increasingly intersecting with eating disorders and disordered eating more broadly, and clear, evidence-based information matters.

One thing to state up front: decisions about GLP-1 medications, especially for anyone with an eating disorder or disordered eating history, belong with a qualified care team. This article is written from an eating-disorder-informed, weight-neutral perspective, and lays out the evidence, not a recommendation for or against any medication. These medications are also prescribed for several different reasons, including diabetes, PMOS, cardiovascular risk reduction, and increasingly binge eating disorder itself.

What the Research Shows, on Both Sides

On one side, there is meaningful but qualified evidence for benefit. A 2026 systematic review and meta-analysis pooled data from 25 randomized controlled trials involving more than 8,000 participants and found consistent associations between GLP-1 receptor agonists and reduced binge eating severity, less loss-of-control eating, and lower disinhibited eating. Most of these trials enrolled participants based on body size rather than an eating disorder diagnosis, and binge eating disorder occurs across all body sizes, so this isn't a direct evidence base for people with BED specifically. Researchers involved were nonetheless cautious, stating that these medications should not replace evidence-based treatments for binge eating disorder, such as cognitive behavioral therapy. The proposed mechanism is at least biologically plausible: GLP-1 medications act on reward and food-preoccupation pathways in the brain, not just on appetite, which may explain why binge eating decreases for some people.

Set against that is a serious and specific risk, rooted in those same reward and appetite pathways. For someone already vulnerable, the same appetite-suppressing mechanism can intensify restriction rather than ease it: any medication that suppresses appetite and drives weight loss carries real risk for someone with an eating disorder or disordered eating, regardless of why it was prescribed. Eating less can intensify food preoccupation, and weight loss itself can feed restrictive patterns, whether or not someone already has a diagnosed eating disorder.

This isn't a hypothetical concern. A 2026 survey of people with eating disorders, published in JAMA Psychiatry, found GLP-1 use across every diagnosis, including more than half of those with binge eating disorder and about a third of those with atypical anorexia. More than 10% reported misusing the medication (taking more or less than prescribed, using it longer than prescribed, tampering with injection equipment, or using it without a prescription), and because the data were self-reported, the real numbers may be higher. For some people, it can become another tool for the eating disorder itself.

Why Screening and Monitoring Matter

In practice, people are often not screened for eating disorders before being prescribed a GLP-1. There is no standard protocol to do so, even though brief, validated screening tools exist. Most prescriptions come from primary care, endocrinology, and weight-management settings, where training in eating disorder assessment varies, and a growing share now come through online and telehealth companies. Intake on some of these platforms can be as brief as an online questionnaire, and physicians and researchers have raised concerns that some prescribe with limited evaluation and follow-up.

The result is that an appetite-suppressing medication can reach someone with active restriction or an eating disorder history without anyone screening for it. Assessment and ongoing monitoring by a clinician who understands eating disorders is what closes that gap.

If You're Already on a GLP-1 and Worried About Your Eating

If you are currently taking a GLP-1 medication and noticing changes in your relationship with food that feel concerning rather than helpful, take it seriously. A few patterns to watch for: skipping meals or saving up appetite for one larger meal instead of eating consistently through the day, secrecy or guilt around eating, using exercise to compensate for what you ate, a return of restrictive rules or behaviors you had previously worked to move away from, or a growing preoccupation with the number on the scale.

Noticing one or more of these is not something to sort out on your own. It means it is time to loop in your care team, whether that is the prescriber, a therapist, or a dietitian, so the pattern can be assessed with real context about your history. These patterns are not always linear, and a medication interacting with them is information, not failure.

Where Nutrition Support Fits

Whatever someone and their care team decide about medication, an eating disorder or disordered eating pattern is not something a medication resolves on its own. The relationship with food, the behaviors, the underlying distress, these are the work of recovery, and they need real support.

As a practice that includes a Certified Eating Disorder Specialist, our role is the nutrition piece of that larger picture: helping rebuild a steadier, less fraught relationship with food, alongside the other members of a care team. We work from a weight-neutral, non-restrictive approach, which matters especially here, because much of what drives eating disorders is tangled up with weight stigma and food rules in the first place.

If you have an eating disorder or disordered eating history and are considering, taking, or reconsidering a GLP-1 medication, that is best navigated with people who understand both sides of it. You do not have to sort it out alone.

If you need support before you're able to connect with a care team, the National Alliance for Eating Disorders has a free helpline with licensed clinicians at 1-866-662-1235 (weekdays), and 988 is available any time by call or text.

The Bottom Line

The research on GLP-1 medications and eating disorders is still developing, and what exists shows both real promise and real risk. There is a real signal that they may help reduce binge eating for some people, and there is real risk both for anyone with an eating disorder and for people who could develop one, since appetite suppression and weight loss can feed or trigger those same patterns. What resolves that tension is not a blanket yes or no, it is honest information, screening, and monitoring by people with eating disorder expertise. If this is your situation, the most important thing is not which article you read, but that the people supporting you actually understand eating disorders and disordered eating.

If you are navigating this and want nutrition support that understands both eating disorders and disordered eating, we would love to help. The simplest next step is to reach out to see if we are a good fit. We see clients via telehealth across Texas and in person in Austin, and we are in network with several major insurers.

Frequently Asked Questions

Can GLP-1 medications help with binge eating disorder? The strongest evidence so far, a 2026 meta-analysis of 25 randomized controlled trials with more than 8,000 participants, found consistent reductions in binge eating severity. Most trials enrolled participants by body size rather than a BED diagnosis, so this isn't direct evidence for BED specifically, and it shouldn't replace treatments like cognitive behavioral therapy. See "What the Research Shows" above for the full picture.

Are GLP-1 medications safe for someone with a history of an eating disorder or disordered eating? It depends on the individual and the care in place. These medications can reinforce harmful patterns for someone with an eating disorder or disordered eating history, so screening and ongoing monitoring by clinicians with eating disorder expertise are essential before deciding. See "Why Screening and Monitoring Matter" above.

Are people screened for eating disorders before being prescribed a GLP-1? Usually not. There is no standard protocol, even though brief, validated screening tools exist, and many prescriptions come from settings where training in eating disorder assessment varies. See "Why Screening and Monitoring Matter" above for more detail.

Can a GLP-1 medication cause an eating disorder? It's not fully settled, but clinicians who specialize in eating disorders have raised this concern directly. Since dieting and food restriction are common precursors reported by many people who go on to develop an eating disorder, any medication that suppresses appetite and drives significant weight loss carries some risk of triggering disordered patterns, particularly in people who are already vulnerable. This risk is not the same for everyone, and it has not been rigorously quantified.

What are warning signs to watch for while taking a GLP-1? Signs to watch for include skipping meals or saving up appetite for one larger meal instead of eating consistently through the day, secrecy or guilt around eating, using exercise to compensate for what you ate, a return of old restrictive rules or behaviors, or a growing preoccupation with weight or the scale. None of these automatically mean something is wrong, but bring them to your care team rather than managing them alone.